UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Jan

    31

    Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape

    Jan

    16

    UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)